{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:09:41Z","timestamp":1787785781688,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Claudin 18.2 (CLDN18.2) has emerged as a promising therapeutic target in advanced gastric cancer (GC). Data on resistance to zolbetuximab due to secondary antigen loss or baseline intrapatient heterogeneity are sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A young female patient with advanced GC and severe anemia and thrombocytopenia due to bone marrow carcinomatosis, treated with zolbetuximab-based therapy, exhibited discordant CLDN18.2 expression between primary and metastatic sites. Histological analysis of the resected Krukenberg metastasis revealed CLDN18.2 negativity, contrasting with the strong, diffuse expression in the primary tumor and bone marrow metastases. Subsequent disease progression occurred predominantly in lymph node metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      This case reveals the potential clinical impact of the heterogeneity of CLDN18.2 expression or secondary loss of antigen on the efficacy of CLDN18.2-targeted therapy. Reassessment of biomarkers at progression could be considered to optimize personalized treatment strategies. Furthermore, this case supports the safety of administering zolbetuximab-based therapy in the setting of bone marrow carcinomatosis, even in the presence of severe thrombocytopenia (platelet count\u2009&lt;\u200950\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l). To our knowledge, this represents the first documented case of CLDN18.2-positive gastric cancer identified by bone marrow biopsy worldwide.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06447-3","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:14:09Z","timestamp":1773922449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: Intrapatient heterogeneity or secondary loss of expression?"],"prefix":"10.1007","volume":"152","author":[{"given":"O.","family":"Morath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Lindig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Katenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Haziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Auletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bauerschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Franiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bergener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Griessbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Crodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"6447_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00432-020-03268-w","volume":"146","author":"L Cheng","year":"2020","unstructured":"Cheng L, Chen S, Wu W, Kuo Z, Wei Z, Meng S, Chen C, Zhang C, He Y (2020) Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis. J Cancer Res Clin Oncol 146:1\u201311. https:\/\/doi.org\/10.1007\/s00432-020-03268-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"6447_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-47608-8","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu MH, Kim HD, Park YS (2024) Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep 14:17648. https:\/\/doi.org\/10.1038\/s41598-024-47608-8","journal-title":"Sci Rep"},{"issue":"5","key":"6447_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","volume":"475","author":"M Dottermusch","year":"2019","unstructured":"Dottermusch M, Kr\u00fcger S, Behrens HM, Halske C, R\u00f6cken C (2019) Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch 475(5):563\u2013571. https:\/\/doi.org\/10.1007\/s00428-019-02624-7","journal-title":"Virchows Arch"},{"key":"6447_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.14744\/ejmo.2017.65365","volume":"1","author":"Y Ergun","year":"2017","unstructured":"Ergun Y, Uncu D, Yaz\u0131c\u0131 O, Ucar G, Karabuga EK, Zengin N (2017) Gastric cancer patients with bone marrow metastasis: a single-center experience and review of the literature. EJMO 1:160\u2013163. https:\/\/doi.org\/10.14744\/ejmo.2017.65365","journal-title":"EJMO"},{"key":"6447_CR5","doi-asserted-by":"publisher","first-page":"12249","DOI":"10.3748\/wjg.v21.i43.12249","volume":"21","author":"H Iguchi","year":"2015","unstructured":"Iguchi H (2015) Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer. World J Gastroenterol 21:12249\u201312260. https:\/\/doi.org\/10.3748\/wjg.v21.i43.12249","journal-title":"World J Gastroenterol"},{"key":"6447_CR6","unstructured":"International Agency for Research on Cancer (2025) Global Cancer Observatory: Cancer Today. https:\/\/gco.iarc.fr\/today (accessed July 7, 2025)"},{"key":"6447_CR7","unstructured":"Jordan K, Jahn F, Feyer P, Karthaus M, Kreye G, Leithold C, et al (2021) Antiemesis in patients undergoing pharmacological cancer therapy. Onkopedia guideline. https:\/\/www.onkopedia.com\/en\/onkopedia\/guidelines\/antiemesis-in-cancer-therapy (accessed July 7, 2025)"},{"issue":"8","key":"6447_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ (2024) Zolbetuximab: first approval. Drugs 84(8):977\u2013983. https:\/\/doi.org\/10.1007\/s40265-024-02056-x","journal-title":"Drugs"},{"key":"6447_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/his.14672","volume":"81","author":"JY Kim","year":"2022","unstructured":"Kim JY, Kim MA, Jung HY, Lee HS (2022) Expression of CLDN18 in primary gastric cancer and its corresponding ovarian metastasis. Histopathology 81:544\u2013552. https:\/\/doi.org\/10.1111\/his.14672","journal-title":"Histopathology"},{"issue":"8","key":"6447_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.esmoop.2022.100762","volume":"33","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y et al (2022) Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. Ann Oncol 33(8):801\u2013811. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762","journal-title":"Ann Oncol"},{"key":"6447_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4143\/crt.2011.43.4.244","volume":"43","author":"JY Kwon","year":"2011","unstructured":"Kwon JY, Yun J, Kim HJ, Kim KH, Kim SH, Lee SC et al (2011) Clinical outcome of gastric cancer patients with bone marrow metastases. Cancer Res Treat 43:244\u2013249. https:\/\/doi.org\/10.4143\/crt.2011.43.4.244","journal-title":"Cancer Res Treat"},{"issue":"10","key":"6447_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G et al (2022) Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(10):1005\u20131020","journal-title":"Ann Oncol"},{"key":"6447_CR13","unstructured":"Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, Faber G, Gockel I, K\u00f6berle D, Lorenzen S, M\u00f6hler M, Pritzkuleit R, R\u00f6cken C, Stahl M, Thuss-Patience P, W\u00f6ll E, Zander T (2025) Gastric cancer: Onkopedia guideline. Gastric Cancer (Onkopedia). https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/magenkarzinom (accessed July 7, 2025)"},{"key":"6447_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e16068","author":"V Massa","year":"2024","unstructured":"Massa V, Salani F, Grelli G, Genovesi V, Vivaldi C, Signorini F et al (2024) Concordance of PD-L1 combined positive score (CPS) between primary gastric cancer and matched peritoneal metastasis. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e16068","journal-title":"J Clin Oncol"},{"issue":"1","key":"6447_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12337-4","volume":"15","author":"S Pak","year":"2025","unstructured":"Pak S, Simon AG, Lyu SI, Tolkach Y, Alakus H, Zander T, Buettner R, Bruns CJ, Schroeder W, Quaas A (2025) The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma. Sci Rep 15(1):28958. https:\/\/doi.org\/10.1038\/s41598-025-12337-4","journal-title":"Sci Rep"},{"issue":"11","key":"6447_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, Nappo F, Businello G, Sbaraglia M, Bergamo F et al (2021) Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med 11(11):1095. https:\/\/doi.org\/10.3390\/jpm11111095","journal-title":"J Pers Med"},{"key":"6447_CR17","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/ijc.30396","volume":"139","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F et al (2016) HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy. Int J Cancer 139:2859\u20132864. https:\/\/doi.org\/10.1002\/ijc.30396","journal-title":"Int J Cancer"},{"key":"6447_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S et al (2022) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28:1189\u20131198. https:\/\/doi.org\/10.1038\/s41591-022-01800-8","journal-title":"Nat Med"},{"key":"6447_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00428-022-03411-5","volume":"482","author":"J Rohde","year":"2023","unstructured":"Rohde J, Rohde M, Huber T, Kaemmerer D, Lupp A (2023) CLDN18 isoform 2 expression in primary gastric adenocarcinomas and matched lymph node metastases. Virchows Arch 482:291\u2013301. https:\/\/doi.org\/10.1007\/s00428-022-03411-5","journal-title":"Virchows Arch"},{"issue":"23","key":"6447_CR20","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14(23):7624\u20137634","journal-title":"Clin Cancer Res"},{"key":"6447_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10120-018-0891-1","volume":"22","author":"S Seo","year":"2018","unstructured":"Seo S, Ryu M, Park Y, Ahn J, Park Y, Park S et al (2018) Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients. Gastric Cancer 22:527\u2013535. https:\/\/doi.org\/10.1007\/s10120-018-0891-1","journal-title":"Gastric Cancer"},{"issue":"8","key":"6447_CR22","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29(8):2133\u20132141","journal-title":"Nat Med"},{"issue":"12","key":"6447_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ et al (2024a) Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med 391(12):1159\u20131162. https:\/\/doi.org\/10.1056\/NEJMc2409512","journal-title":"N Engl J Med"},{"issue":"8","key":"6447_CR24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S1470-2045(24)00123-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA et al (2024b) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 25(8):789\u2013801. https:\/\/doi.org\/10.1016\/S1470-2045(24)00123-7","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"6447_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e16035","volume":"40","author":"J Xiao","year":"2022","unstructured":"Xiao J, Cao T, Du G, Zhai X, Li S (2022) Clinicopathological features, treatment outcome and survival of 115 cases of gastric adenocarcinoma with bone marrow metastasis and disseminated intravascular coagulation. J Clin Oncol 40(16_suppl):e16120","journal-title":"J Clin Oncol"},{"key":"6447_CR26","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0748","author":"Z Xiaohui","year":"2022","unstructured":"Xiaohui Z, Shanshan L, Taiyuan C, Ge D, Hongen Y, Lishuo S et al (2022) Docetaxel and fluorouracil as first-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation. Future Oncol. https:\/\/doi.org\/10.2217\/fon-2022-0748","journal-title":"Future Oncol"},{"key":"6447_CR27","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.1016\/j.annonc.2024.08.676","volume":"35","author":"RH Xu","year":"2024","unstructured":"Xu RH, Ruan D, Luo S, Liang X, Niu Z, Dang Q et al (2024) CLDN18.2 targeted antibody-drug conjugate (ADC), SHR A1904, in patients with gastric\/gastroesophageal junction cancer (GC\/GEJC): a phase I study. Ann Oncol 35:S487\u2013S488. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.676","journal-title":"Ann Oncol"},{"key":"6447_CR28","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.5833\/jjgs.18.2288","volume":"18","author":"Y Yamamura","year":"1985","unstructured":"Yamamura Y, Kito T, Yamada E (1985) Clinical evaluation on bone and bone marrow metastasis of gastric carcinoma. Jpn J Gastroenterol Surg 18:2288\u20132293. https:\/\/doi.org\/10.5833\/jjgs.18.2288","journal-title":"Jpn J Gastroenterol Surg"},{"key":"6447_CR29","doi-asserted-by":"publisher","first-page":"S514","DOI":"10.1016\/j.annonc.2024.08.717","volume":"35","author":"J Yu","year":"2024","unstructured":"Yu J, Sun Y, Liu T, Gao SG, Guo Z, Liang X et al (2024) 651P phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and\/or metastatic solid tumors. Ann Oncol 35:S514. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.717","journal-title":"Ann Oncol"},{"key":"6447_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cac2.12277","volume":"42","author":"X Zhai","year":"2022","unstructured":"Zhai X, Wang C, Li S, Cao T, Du G, Zhang Y et al (2022) Bone marrow metastasis from advanced gastric cancer complicated with disseminated intravascular coagulation: a highly aggressive but manageable disease subtype. Cancer Commun 42:350\u2013354. https:\/\/doi.org\/10.1002\/cac2.12277","journal-title":"Cancer Commun"},{"key":"6447_CR31","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou KI et al (2020) Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma. Clin Cancer Res 26:6453\u20136463. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2085","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06447-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06447-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:29:51Z","timestamp":1781641791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06447-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6447"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06447-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Written informed consent has been obtained from the patient for the publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"70"}}